Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis

Annals of the Rheumatic Diseases

Volumn 60, Issue 4, 2001, Pages 385-390

  Lamprecht, P ^a   Moosig, F ^b   Gause, A ^a   Herlyn, K ^a   Csernok, E ^a   Hansen, H ^c   Gross, W L ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Stadtisches Krankenhaus Kiel   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; CD30 ANTIGEN; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C4; CRYOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; RHEUMATOID FACTOR;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMPLEMENT HEMOLYSIS TEST; CRYOGLOBULINEMIA; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GERMANY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; MALE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SERUM; T LYMPHOCYTE; VASCULITIS;

ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD30; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; COMPLEMENT C3C; COMPLEMENT C4; COMPLEMENT HEMOLYTIC ACTIVITY ASSAY; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-ALPHA; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VASCULITIS;

EID: 0035071390     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.60.4.385     Document Type: Article

References (43)

1. Nomenclature of systemic vasculitides. Proposal of an international conference
2. The spectrum and treatment of virus-associated vasculitides
3. Biologic and clinical significance of cryoglobulins. A report of 86 cases
4. Mixed cryoglobulinemia after hepatits C virus: More or less ambiguity
5. Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis
6. Cryoglobulinemic vasculitis
7. Relation between infection and autoimmunity in mixed cryoglobulinemia
8. Serum interleukin 2 and soluble interleukin 2 receptor in chronic active hepatitis C: Effect of interferon therapy
9. Circulating soluble intercellular adhesion molecule-1 in type C viral hepatitis
10. Birmingham vasculitis activity score, disease extent index and complement C3c reflect disease activity best in hepatitis C virus-associated cryoglobulinemic vasculitis
11. Disease severity in rheumatoid arthritis: Relationship of plasma tumor necrosis factor-α, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures
12. Churg-Strauss syndrome. Serum markers of lymphocyte activation and endothelial damage
13. GISC protocol experience in the treatment of essential mixed cryoglobulinemia
14. Cryoglobulinaemias: A multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease
15. Cryoglobulinemia in chronic hepatitis C infection: Prevalence, clinical manifestations, response to interferon treatment and analysis of cryopreciptates
16. High levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis
17. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis
18. Vital assessment of vasculitis
19. Wegener's granulomatosis. Anatomic correlates, a proposed classification
20. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis
21. Wegener's granulomatosis: Disease course, assessment of activity and extent and treatment
22. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis
23. Mixed cryoglobulinemia. A guide to drug treatment
24. Systemic necrotizing vasculitis
25. Interferon-α treatment of hepatitis C virus-associated cryoglobulinemia
26. Hepatitic C
27. Interferon in the treatment of mixed cryoglobulinemia
28. Interferon-α in mixed cryoglobulinemia patients. A randomized, crossover-controlled trial
29. Serum complement pattern in essential mixed cryoglobulinemia
30. A newly described control mechanism of complement activation in patients with mixed cryoglobulinemia (cryoglobulins and complement)
31. Immune complexes and complement profile in essential mixed cryoglobulinemia before and after plasma exchange
32. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis
33. Circulating adhesion molecules ICAM-1, VCAM-1 and E-selectin in systemic vasculitis: Marked differences between Wegener's granulomatosis and systemic lupus erythematosus
34. Naive and memory T cells infiltrates in chronic hepatits C: Phenotypic changes with interferon treatment
35. Hohe serumspiegel von ICAM-1 bei der aktiven Wegener'schen Granulomatose
36. Cell adhesion molecules in vasculitis
37. Hodgkin's disease: A tumor with disturbed immunological pathways
38. Serum levels of soluble CD30 in chronic hepatitis B virus infection
39. High serum level of soluble CD30 in acute primary HIV-1 infection
40. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity
41. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease
42. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease
43. Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon-alfa